Pre-launch intelligence layer

Access regularly updated biotech asset intelligence.

BioAssetIQ helps biotech leadership bring public evidence, internal asset knowledge, market context, and fresh asset data into one source-backed asset view — ready to shape investor, partner, board, and leadership materials.

Request early access
The problem BioAssetIQ solves

Public evidence, internal knowledge and market context are too often fragmented.

Biotech teams rarely lack information. The harder problem is turning public sources, proprietary asset knowledge and competitive market signals into one clear view for stakeholder decisions.

Public intelligenceScientific, clinical, regulatory and market signals sit across disconnected public sources.
Internal evidenceTeams hold valuable proprietary context in reports, working decks, analyses and expert notes.
Market researchCompetitive movement, comparable assets and investor context are hard to monitor consistently.
Stakeholder materialsInvestor, partner and board materials often require last-minute interpretation and alignment.
Public + BYOD intelligence

BioAssetIQ turns public and client-owned data into stakeholder-ready asset intelligence.

BioAssetIQ combines regularly updated public information with a company’s own materials — BYOD, bring your own data — to support market research, asset positioning and source-backed stakeholder materials.

Public intelligenceLatest public evidence, market context and competitive signals organized for decision use.
Bring your own dataInternal reports, working decks and proprietary context structured alongside public sources.
Stakeholder-ready outputsClear asset views for investor, partner, board and leadership conversations.
Built for high-stakes asset calls

For teams that cannot afford shallow interpretation.

BioAssetIQ is designed for people who need to understand not just what the data says — but what it means for the next decision.

Biotech leaders

Frame asset readiness and strategic options earlier.

Investors

Separate signal from narrative noise before conviction forms.

Pharma BD

Evaluate partnering opportunities through structured evidence.

Strategy teams

Turn scattered sources into executive-ready perspectives.

From fragmented evidence to readiness

New evidence arrives. The meeting does not move.

BioAssetIQ gives biotech teams a structured way to keep the asset view current, understand the competitive landscape and translate evidence into materials the room can actually use.

Before BioAssetIQ

Fragmented evidence

Public sources, market notes, internal analyses and working decks sit apart. Leadership must manually decide what matters, what can be said and how to say it.

With BioAssetIQ

Asset intelligence

Public intelligence and BYOD materials are structured into a source-backed view of evidence, risks, context and stakeholder relevance.

Market research

Competitive landscape

Teams can follow comparable assets, market movement and strategic signals with a clearer research workspace for a competitive biotech market.

When it matters

Ready for the room

Investor, partner, board and leadership materials can be shaped from the same evidence base, with clearer narrative control and decision readiness.

Team

Built from 20+ years inside biotech, clinical research and stakeholder decision-making.

BioAssetIQ is shaped by first-hand experience of the funding, partnering and communication challenges that biotech companies face when promising science needs the right commercial path forward.

Hannu Rautanen

Hannu Rautanen

Founder · Clinical research, biotech partnerships & business development

Hannu has spent more than 20 years working across the clinical research industry with CROs, biotech and pharmaceutical companies. Throughout his career in business development, outsourcing and consulting, he has seen first-hand how many biotech companies struggle to secure the right funding, partnerships and strategic support at the right time.

Drawing on his deep industry experience, global professional network and accumulated market insight, Hannu set out with the founding team to build a service that addresses this underserved part of the biotech business landscape. BioAssetIQ was created to help biotech companies connect their scientific potential with the commercial, financial and partnership opportunities needed to move forward.

Peter Larnholt

Peter Larnholt

Founder · AI-native venture building, technology leadership & transformation

Peter has spent more than 30 years building and scaling startup companies, including over 15 years in telecom C-level technology executive roles. Across his career, he has focused on bridging business and technology — helping organizations turn complex technological change into practical growth, better customer engagement and faster execution.

Today, Peter works at the forefront of AI-native company building. Together with his teams, he creates, designs, builds and brings to market AI-native ventures across the Middle East, Europe and Latin America. His teams help business leaders accelerate AI-native transformation and use AI to unlock new levels of efficiency, speed and strategic execution.

For BioAssetIQ, Peter and his team have worked together with Hannu to build the AI-native product foundation — combining deep biotech market insight with modern AI venture-building capability.

Pre-launch access

Be first to see the BioAssetIQ intelligence layer.

Join the pre-launch list for early previews, product updates and first access conversations.

Request early access